Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of Olopatadine Nasal Spray
2017-003846-26Phase 3
- Sponsor
- Alcon Inc.
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial rhinitis comparing Olopatadine nasal spray 0.6% with Vehicle nasal spray (2 arms). Primary endpoint: Mean Response to the Subject-Rated Relief Assessment at Day 30.
02
Drugs
olopatadine
03
Conditions
perennial rhinitis
Beyond the preview
Go deeper on 2017-003846-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003846-26.